SecBot SecBot
PRESS-RELEASE ·Filed Mar 26, 2026

LFCR

Lifecore Biomedical, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight ▲ Bullish

Traders should monitor Lifecore’s progress on these site transfers and any future announcements regarding commercial ramp-up timelines. The 2028 revenue contribution suggests a medium-term catalyst; consider positioning ahead of potential scale-up updates or additional contract wins.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.87
T+0 close · Mar 26, 2026 · via day close
Latest settled
+45.27%
T+60 · $5.62
Vs SPY
+31.32%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 26 $3.87entry
  2. T+1 · 8mo ago −5.43%α −3.75% · $3.66
  3. T+5 · 8mo ago −0.78%α −2.41% · $3.84
  4. T+20 · 7mo ago +29.72%α +19.05% · $5.02
  5. T+60 · 5mo ago +45.27%α +31.32% · $5.62
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Lifecore Biomedical announced two new CDMO manufacturing agreements with an existing U.S. biopharmaceutical customer: one for a commercial site transfer of a currently marketed product, and another to expand manufacturing of an ophthalmic product into a new delivery system previously made in Europe. These agreements are expected to contribute to commercial revenue starting in 2028 and mark the company's fourth site transfer win in five months, reinforcing its strategic focus on late-stage, high-value programs.

Key Facts

  • Lifecore signed two manufacturing agreements with an existing U.S. biopharmaceutical customer.
  • One agreement involves a commercial site transfer of a currently marketed product, requiring technical transfer and PPQ batches at commercial scale.
  • The second agreement expands manufacturing of an ophthalmic product to a new delivery system, shifting production from Europe to Lifecore.
  • These are the fourth commercial site transfer agreements signed in five months.
  • Management expects both programs to contribute to commercial revenue in 2028.
  • The deals are additive to Lifecore’s late-stage pipeline and reflect growing customer trust.

Financial Impact

Expected to generate meaningful commercial revenue starting in 2028, though no specific dollar amounts disclosed.

revenuepipeline value

Risk Factors

  • Revenue contribution is not expected until 2028, introducing execution and timing risk.
  • Forward-looking statements are subject to regulatory, technical, and customer-related uncertainties.
  • No financial terms or deal values were disclosed, limiting near-term financial impact assessment.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3262848

Track record

20 reports on LFCR

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +14.34% at T+20 after the Jul 2, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $6.42 Now $6.42 +0.08% settles Nov 18
  2. Nov 13, 20263d ago DEFM14A Neutral 6/10 Entry $6.42 Now $6.42 +0.00% settles Nov 17
  3. Nov 5, 202611d ago 8-K / DEFA14A Neutral 5/10 Entry $6.40 to $6.36 Now $6.42 +0.31% ▼ −0.63% −0.94% vs SPY
  4. Nov 4, 202612d ago 8-K Bearish 6/10 No price data
  5. Nov 4, 202612d ago Press Release Bearish 5/10 Entry $6.44 to $6.40 Now $6.42 +0.31% ▲ +0.62% −3.79% vs SPY
  6. Oct 30, 202617d ago PREM14A Neutral 5/10 Entry $6.39 to $6.42 Now $6.42 +0.47% ▲ +0.47% +0.17% vs SPY
  7. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $6.37 to $6.37 Now $6.42 +0.78% · 0.00% +1.18% vs SPY
  8. Sep 28, 20267w ago SC 13D/A Bullish 7/10 Entry $6.59 to $6.58 Now $6.42 −2.58% ▼ −0.15% +0.05% vs SPY
  9. Sep 28, 20267w ago DEFA14A Bullish 7/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
  10. Sep 28, 20267w ago 8-K Bullish 8/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 7h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026